Drug Trial Radar · NCT06934967
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
Oct 14, 2031
Study completion Nov 13, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label, single arm, multicenter, phase 3 study is to assess the pharmacokinetics of iptacopan in pediatric patients and to assess whether iptacopan is safe and well tolerated when used for the treatment of pediatric paroxysmal nocturnal hemoglobinuria (PNH) patients 2 to \< 18 years of age.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
LNP023Drug
Cohort 1-administered orally a dosing scheme of 200 mg twice-daily (two 100 mg capsules). Cohort 2- administered orally a dosing scheme based on weight at the Day 1, Week 12, 26 and 38.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 26 weeks
- PK parameter (Cmax)Time frame: Week 2
- PK parameter (AUClast)Time frame: Week 2
- PK parameter (AUCtau)Time frame: Week 2
- PK parameter (Ctrough)Time frame: Weeks 2, 4, 12 and 26
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
Childrens Healthcare of Atlanta
Atlanta, Georgia · Recruiting
Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
St Jude Childrens Research Hospital
Memphis, Tennessee · Recruiting
Novartis Investigative Site
Brasília, Federal District, Brazil · Recruiting
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
Santo André, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany · Recruiting
Novartis Investigative Site
Genova, GE, Italy · Recruiting
Novartis Investigative Site
Utrecht, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.